Last 12 months
Inside the activity.
0 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2019 Filed Mar 21, 2019 22:08 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
SaleCommon Stock | 1,823 | $82.33 | $150,087.59 |
DisclosureSEC source: 0001179110-19-004151 · edgar.xml · nonDerivative · entry 3 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,746 F2 · price: The price reported in Column 4 is the exact price of $82.33. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 21, 2019 Filed Mar 21, 2019 22:08 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
Exercise / conversionCommon Stock | 1,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004151 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| March 21, 2019 Filed May 10, 2019 15:25 UTC Amendment |
Ngo Nhat HEVP, Marketing, S & B D
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 1,823 | $0.00 Strike: $16.70 | $0.00 |
DisclosureSEC source: 0001179110-19-005815 · edgar.xml · derivative · entry 4 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,823 shares Expires 2022-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| March 21, 2019 Filed May 10, 2019 15:25 UTC Amendment |
Ngo Nhat HEVP, Marketing, S & B D
|
SaleCommon Stock | 1,823 | $82.33 | $150,087.59 |
DisclosureSEC source: 0001179110-19-005815 · edgar.xml · nonDerivative · entry 3 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,134 F2 · price: The price reported in Column 4 is the exact price of $82.33. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 21, 2019 Filed May 10, 2019 15:25 UTC Amendment |
Ngo Nhat HEVP, Marketing, S & B D
|
Exercise / conversionCommon Stock | 1,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005815 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| March 17, 2019 Filed Mar 20, 2019 23:00 UTC |
Seim Robin GenePresident, Global A & M A
|
OtherCommon Stock | 41,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004128 · edgar.xml · nonDerivative · entry 2 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,953 F1 · shares: The disposition is reported due to cancellation of the reporting person's unvested awards in connection with his retirement as an Officer. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 15:17 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
Tax withholdingCommon Stock | 202 | $84.74 | $17,117.48 |
DisclosureSEC source: 0001179110-19-003965 · edgar.xml · nonDerivative · entry 2 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,463 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 15, 2019 Filed May 22, 2019 22:03 UTC Amendment |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
Tax withholdingCommon Stock | 202 | $84.74 | $17,117.48 |
DisclosureSEC source: 0001179110-19-006517 · edgar.xml · nonDerivative · entry 2 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,112 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
Exercise / conversionStock Options NQ (Right to buy) · Derivative | 7,332 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · derivative · entry 12 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,332 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
Exercise / conversionStock Options NQ (Right to buy) · Derivative | 628 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · derivative · entry 11 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 628 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
Exercise / conversionStock Options NQ (Right to buy) · Derivative | 908 | $0.00 Strike: $27.70 | $0.00 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · derivative · entry 10 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 908 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
SaleCommon Stock | 8,868 | $83.79 | $743,031.98 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · nonDerivative · entry 6 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,024 F3 · price: The price reported in Column 4 is the average price of $83.7880. The sold price range between $83.25 to $84.02. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
Exercise / conversionCommon Stock | 8,868 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · nonDerivative · entry 5 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
SaleCommon Stock | 1,132 | $83.68 | $94,721.57 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · nonDerivative · entry 4 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,024 F2 · price: The price reported in Column 4 is the exact price of $83.6763. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionStock Options NQ (Right to buy) · Derivative | 5,220 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001179110-19-003767 · edgar.xml · derivative · entry 9 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,220 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionStock Options NQ (Right to buy) · Derivative | 13,621 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-19-003767 · edgar.xml · derivative · entry 8 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,621 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionStock Options NQ (Right to buy) · Derivative | 2,345 | $0.00 Strike: $32.78 | $0.00 |
DisclosureSEC source: 0001179110-19-003767 · edgar.xml · derivative · entry 7 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,345 shares Expires 2025-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionStock Options NQ (Right to buy) · Derivative | 1,094 | $0.00 Strike: $27.70 | $0.00 |
DisclosureSEC source: 0001179110-19-003767 · edgar.xml · derivative · entry 6 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,094 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 13,379 | $84.07 | $1,124,771.19 |
DisclosureSEC source: 0001179110-19-003767 · edgar.xml · nonDerivative · entry 5 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,873 F4 · price: The price reported in Column 4 is the average price of $84.0699. The sold price range between $84.00 to $84.71. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 8,901 | $84.07 | $748,306.18 |
DisclosureSEC source: 0001179110-19-003767 · edgar.xml · nonDerivative · entry 4 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,252 F3 · price: The price reported in Column 4 is the average price of $84.0699. The sold price range between $83.02 to $83.98. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 22:40 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionCommon Stock | 22,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003767 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
Exercise / conversionStock Options NQ (Right to buy) · Derivative | 1,172 | $0.00 Strike: $34.02 | $0.00 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · derivative · entry 9 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,172 shares Expires 2025-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
Exercise / conversionStock Options NQ (Right to buy) · Derivative | 4,536 | $0.00 Strike: $4,536.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · derivative · entry 8 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,536 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
Exercise / conversionStock Options NQ (Right to buy) · Derivative | 4,088 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · derivative · entry 7 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,088 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
SaleCommon Stock | 9,796 | $83.94 | $822,241.95 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · nonDerivative · entry 3 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,156 F1 · price: The price reported in Column 4 is the average price of $83.9365. The sold price range between $83.60 to $84.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Taborga Jorge R.EVP, Global R & D
|
Exercise / conversionCommon Stock | 9,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003768 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 2,224 | $83.00 | $184,592.00 |
DisclosureSEC source: 0001179110-19-003767 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,873 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F1 · price: The price reported in Column 4 is the exact price of $83.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Seim Robin GenePresident, Global A & M A
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 2,344 | $0.00 Strike: $34.02 | $0.00 |
DisclosureSEC source: 0001179110-19-003766 · edgar.xml · derivative · entry 8 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,344 shares Expires 2025-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Seim Robin GenePresident, Global A & M A
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 5,442 | $0.00 Strike: $27.70 | $0.00 |
DisclosureSEC source: 0001179110-19-003766 · edgar.xml · derivative · entry 7 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,442 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Seim Robin GenePresident, Global A & M A
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 7,165 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-19-003766 · edgar.xml · derivative · entry 6 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,165 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Seim Robin GenePresident, Global A & M A
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 13,849 | $0.00 Strike: $44.25 | $0.00 |
DisclosureSEC source: 0001179110-19-003766 · edgar.xml · derivative · entry 5 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,849 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Seim Robin GenePresident, Global A & M A
|
SaleCommon Stock | 21,504 | $83.70 | $1,799,861.15 |
DisclosureSEC source: 0001179110-19-003766 · edgar.xml · nonDerivative · entry 4 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,618 F3 · price: The price reported in Column 4 is the average price of $83.6989. The sold price range between $83.36 to $84.12. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Seim Robin GenePresident, Global A & M A
|
SaleCommon Stock | 7,296 | $83.70 | $610,667.17 |
DisclosureSEC source: 0001179110-19-003766 · edgar.xml · nonDerivative · entry 3 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,122 F2 · price: The price reported in Column 4 is the average price of $83.6989. The sold price range between $82.05 to $83.35. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 22:40 UTC |
Seim Robin GenePresident, Global A & M A
|
Exercise / conversionCommon Stock | 28,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003766 · edgar.xml · nonDerivative · entry 2 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 00:28 UTC |
Seim Robin GenePresident, Global A & M A
|
Tax withholdingCommon Stock | 1,129 | $84.27 | $95,140.83 |
DisclosureSEC source: 0001179110-19-003479 · edgar.xml · nonDerivative · entry 2 Seim Robin Gene · CIK 0001351911 · President, Global A & M A 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,618 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 00:29 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 6,270 | $84.27 | $528,372.90 |
DisclosureSEC source: 0001179110-19-003483 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,523 F3 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 00:29 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Tax withholdingCommon Stock | 597 | $84.27 | $50,309.19 |
DisclosureSEC source: 0001179110-19-003481 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,504 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 00:29 UTC |
Kuipers Peter J.Executive V P& CFO
|
Tax withholdingCommon Stock | 996 | $84.27 | $83,932.92 |
DisclosureSEC source: 0001179110-19-003482 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,097 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 00:28 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
Tax withholdingCommon Stock | 797 | $84.27 | $67,163.19 |
DisclosureSEC source: 0001179110-19-003480 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,772 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 00:27 UTC |
Taborga Jorge R.EVP, Global R & D
|
Tax withholdingCommon Stock | 597 | $84.27 | $50,309.19 |
DisclosureSEC source: 0001179110-19-003478 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · EVP, Global R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,156 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 19:39 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
Exercise / conversionStock Options NQ (right to buy) · Derivative | 6,500 | $0.00 Strike: $32.21 | $0.00 |
DisclosureSEC source: 0001179110-19-003006 · edgar.xml · derivative · entry 5 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,500 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 19:39 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
SaleCommon Stock | 2,846 | $85.28 | $242,700.62 |
DisclosureSEC source: 0001179110-19-003006 · edgar.xml · nonDerivative · entry 4 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,665 F3 · price: The price reported in Column 4 is the Average price of $85.2778. The share price were between $85.30 to $85.33. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 19:39 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
SaleCommon Stock | 6,500 | $85.03 | $552,678.75 |
DisclosureSEC source: 0001179110-19-003006 · edgar.xml · nonDerivative · entry 3 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,511 F2 · price: The price reported in Column 4 is the Average price of $85.0275. The share price were between $85.00 to $85.15. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 19:39 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
Exercise / conversionCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003006 · edgar.xml · nonDerivative · entry 2 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 22, 2019 23:18 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 6,046 | $85.84 | $518,998.31 |
DisclosureSEC source: 0001179110-19-002423 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,793 F5 · price: The price reported in Column 4 is the Average price of $85.8416. The share price were between $85.70 to $86.18. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2019 Filed Feb 22, 2019 23:18 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 13,954 | $85.40 | $1,191,702.30 |
DisclosureSEC source: 0001179110-19-002423 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,839 F4 · price: The price reported in Column 4 is the Average price of $85.4022. The share price were between $84.70 to $85.69. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2019 Filed Feb 16, 2019 00:01 UTC |
PETERSMEYER GARY SDirector
|
SaleCommon Stock | 1,000 | $82.26 | $82,257.40 |
DisclosureSEC source: 0001179110-19-002023 · edgar.xml · nonDerivative · entry 2 PETERSMEYER GARY S · CIK 0001206986 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,013 F1 · price: The price reported in Column 4 is the exact price of $82.2574. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:49 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
GrantStock Option (Right to Buy) · Derivative | 12,759 | $0.00 Strike: $78.91 | $0.00 |
DisclosureSEC source: 0001179110-19-002030 · edgar.xml · derivative · entry 4 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,759 Underlying: Common Stock · 12,759 shares Expires 2029-02-12 F1 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:49 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
GrantCommon Stock | 3,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002030 · edgar.xml · nonDerivative · entry 3 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,569 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2020 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2020 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 13, 2019 Filed Feb 16, 2019 00:49 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
GrantCommon Stock | 3,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002030 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,073 F2 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.